Immunome, Inc. (IMNM) Financials

IMNM Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 619.8 million 31.1 million
Dec. 31, 2025 683.2 million 48.8 million
Sept. 30, 2025 299.4 million 35.5 million
June 30, 2025 296.3 million 27.0 million

IMNM Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -61.6 million 8.0 million
Dec. 31, 2025 -52.0 million 7.9 million
Sept. 30, 2025 -41.6 million 6.7 million
June 30, 2025 -50.3 million 5.3 million

IMNM Net Income

No data available :(

IMNM Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 582.7 million 3.7 million -
Dec. 31, 2025 653.5 million 3.9 million 3.9 million
Sept. 30, 2025 272.6 million 4.0 million 4.0 million
June 30, 2025 268.0 million - 4.1 million

IMNM Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 113.1 million
Dec. 31, 2025 87.4 million
Sept. 30, 2025 88.0 million
June 30, 2025 87.0 million

IMNM Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 3.0 million 46.4 million 13.0 million -
Dec. 31, 2025 4.0 million 60.8 million 12.1 million -
Sept. 30, 2025 1.1 million 49.2 million 10.9 million -
June 30, 2025 905000 40.5 million 10.0 million -

IMNM Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 753000
Dec. 31, 2025 - 776000
Sept. 30, 2025 - 49.2 million
June 30, 2025 4.0 million 720000

IMNM

Price: $18.07

52 week price:
7.96
27.65

Earnings Per Share: -2.39 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 8759

Market Capitalization: 1.9 billion

Links: